Multiples Myelom: Rezidiv
00:00 Welcome: Klaus Eisenbeisz & Prof. Scheid 00:35 Study: iMMagine-1 06:53 Significance for everyday clinical practice 08:16 Study: inMMyCAR (In-vivo CAR-T) 14:44 Significance for everyday clinical practice 16:26 Study: MAJESTEC-3 (Antibody combination) 25:28 Significance for everyday clinical practice 27:17 Discussion & Q&A about the studies 33:10 Closing remarks - Send us your feedback via email! [email protected]
▶︎
KEM Knowledge: Less and less chemotherapy for many breast cancer patients (NEW!)
▶︎
Multiples Myelom: Erstlinientherapie
▶︎
ASH 2024 Schwerpunkt neue Therapien im Rezidiv
▶︎
Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained
▶︎
HOLY UX Academy_2.4_HandsOn Quantitative Forschung I Fragetypen
▶︎
Managing Myeloma Symptoms: Infection Prevention, Bone Health, Kidney Care & Side Effect Management
▶︎
How does chemotherapy work? A brief comparison to immunotherapy.
▶︎
Living with PNH - The Discussion Panel
▶︎
Finanzplanung und Finanzierung
▶︎
Talkrunde zum Multiples Myelom
▶︎
Immunotherapy for cancer: Utilizing the body's natural defenses
▶︎
Instant Focus Mode – 40Hz Gamma Brainwave Music for Deep Focus & Productivity
▶︎
🚨Klatsche für den Spiegel! Gericht verbietet Ulmen-Berichterstattung! | NIUS Live, 24.06.26
▶︎
Learn To See What God Sees When He Looks At You
▶︎
Optimierung des Energiemanagements durch K.I. - Vortrag vom 22. Februar 2024 in Kassel
▶︎
Onkopilotin talks! Episode 16 - Metastasiert oder nicht? Was die Brustkrebsdiagnose bedeutet
▶︎
Early Signs of Multiple Myeloma: Symptoms, MGUS, and When to See a Doctor
▶︎
Trump Tries to Catch Reflecting Pool “Vandals” & Miami Gets a Scottish Takeover | The Daily Show
▶︎
Neues zum Multiplen Myelom 1：Bisphosphonat und klassische Medikamente - EHA-Kongress 2023
▶︎